Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Archives of Dermatology

• Publication date

  1992-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHDERM.128.6.781PMID 1376102PMCID PMC3208344
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatotrophic effects of FK506 in dogs.

  1991cited by this paper
• Chemistry and biology of the immunophilins and their immunosuppressive ligands.

  1991cited by this paper
• Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis.

  1990cited by this paper
• Four years of experience with cyclosporin A for psoriasis

  1990cited by this paper
• Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

  1990cited by this paper
• Liver, Kidney, and Thoracic Organ Transplantation Under FK 506

  1990cited by this paper
• Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506

  1990cited by this paper
• The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.

  1989cited by this paper
• FK 506 for liver, kidney, and pancreas transplantation.

  1989cited by this paper
• Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells.

  1989cited by this paper
• Immunologic control of hemopoiesis: implications for quality of the graft after allogeneic bone marrow transplantation.

  1987cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

  1987cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

  1987cited by this paper
• A highly sensitive method to assay FK-506 levels in plasma.

  1987cited by this paper
• Cyclosporine improves psoriasis in a double-blind study.

  1986cited by this paper
• Convulsions with an occult neural-crest tumor.

  1979cited by this paper
• Cyclosporin A for psoriasis.

  1979cited by this paper
• Severe psoriasis--oral therapy with a new retinoid.

  1978cited by this paper

• Voclosporin: A comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus

  2025cites this paper
• Successful treatment of fulminant and recurrent lymphocytic myocarditis with calcineurin inhibitors

  2024cites this paper
• Optimal Practices in the Delivery of Aesthetic Medical Care to Patients on Immunosuppressants and Immunomodulators: A Systematic Review of the Literature.

  2024cites this paper
• Calcineurin inhibitor‐related hyperkalemia is caused by hyporeninemic hypoaldosteronism and fludrocortisone is an effective treatment: Report of a case series and review of the literature

  2024cites this paper
• Systemic calcineurin inhibitors tacrolimus and voclosporin: a review of off-label dermatologic uses.

  2023cites this paper
• The Effect of In Utero Exposure to Maternal Inflammatory Bowel Disease and Immunomodulators on Infant Immune System Development and Function

  2023cites this paper
• Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety

  2022cites this paper
• Tacrolimus as a therapeutic alternative in psoriasis: A retrospective observational study.

  2021cites this paper
• From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment

  2021cites this paper
• Graft Versus Host Disease (GHVD) in Critically Ill Oncologic Patients

  2018cites this paper
• Choosing Topical Drug Candidate: Historical Overview

  2017cites this paper
• Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition

  2017cites this paper
• Posibles indicaciones del tratamiento de las enfermedades autoinmunes con tacrolimus

  2017cites this paper
• Dermal Drug Selection and Development

  2017cites this paper
• Chapter 2 Choosing Topical Drug Candidate : Historical Overview 2 . 1 The Pragmatic Topical Drug Development

  2017cites this paper
• Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis

  2016cites this paper
• Treatment of New-Onset Psoriasis Post-Kidney Transplant

  2016cites this paper
• Tacrolimus for the management of psoriasis: clinical utility and place in therapy

  2016cites this paper
• Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases

  2016cites this paper
• Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases

  2015cites this paper
• Interleukin 10 Treatment of Psoriasis

  2015cites this paper
• Nail psoriasis: An updated review of clinical reports on therapy and formulation aspects for topical delivery

  2015cites this paper
• The Far Side of Vascular Injury

  2015cites this paper
• Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.

  2014cites this paper
• Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

  2014cites this paper
• Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis

  2014cites this paper
• Efficacy of Topical Calcineurin Inhibitors in Psoriasis

  2014cites this paper
• Biological Treatment of Psoriasis

  2013cites this paper
• The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients

  2012cites this paper
• Putting together the psoriasis puzzle: an update on developing targeted therapies

  2012cites this paper
• Anti-cytokine therapies for psoriasis.

  2011cites this paper
• Fk506 Binding Protein 12 Deficiency in Endothelial and Hematopoietic Cells Decreases Regulatory T Cells and Causes Hypertension

  2011cites this paper
• Effects of tacrolimus on IFN-γ signaling in keratinocytes: possible mechanisms by which tacrolimus affects IFN-γ-dependent skin inflammation.

  2011cites this paper
• Tacrolimus: 10 years of successful clinical application

  2010cites this paper
• Psoriasis: what is new in nonbiologic systemic therapy in the era of biologics?

  2010cites this paper
• Charakterisierung der funktionellen Rolle von Wnt5a in Keratinozyten bei der Psoriasis vulgaris

  2010cites this paper
• Anti-cytokine therapeutics: history and update.

  2009cites this paper
• Progress in understanding the immunopathogenesis of psoriasis.

  2009cites this paper
• A global gene expression analysis of the peripheral blood mononuclear cells reveals the gene expression signature in psoriasis.

  2009cites this paper
• Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways

  2008cites this paper
• Immunosuppresseurs systémiques en dermatologie

  2008cites this paper
• Inmunosupresores sistémicos en dermatología

  2008cites this paper
• Tacrolimus: approved and unapproved dermatologic indications/uses-physician's sequential literature survey: part II.

  2008cites this paper
• Systemic ciclosporin and tacrolimus in dermatology

  2007cites this paper
• Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research

  2007cites this paper
• Topical Calcineurin Inhibitors

  2006cites this paper
• Chapter 10 – Skin and Bone Disorders

  2006cites this paper
• Basic immunosuppressive drugs outside solid organ transplantation

  2006cites this paper
• Therapeutic options in the treatment of psoriasis and atopic dermatitis.

  2005cites this paper
• Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product Calcipressin 1 (or RCAN1) in disease

  2005cites this paper
• Topical tacrolimus in the treatment of inverse psoriasis in children.

  2005cites this paper
• Getting under the skin: the immunogenetics of psoriasis

  2005cites this paper
• Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus

  2005cites this paper
• Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules.

  2005cites this paper
• Novel pharmacological approaches in the treatment of psoriasis

  2005cites this paper
• Topical treatment of atopic dermatitis.

  2004cites this paper
• Nontumoral dermatologic problems after liver transplantation

  2004cites this paper
• Topical pharmacokinetics for a rational and effective topical drug development process.

  2004cites this paper
• Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.

  2004cites this paper
• FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice

  2004cites this paper
• Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases

  2004cites this paper
• Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report.

  2004cites this paper
• Recent advances in the treatment of psoriatic arthritis

  2004cites this paper
• Other Potential Dermatological Indications for Tacrolimus

  2004cites this paper
• Tacrolimus ointment is effective for facial and intertriginous psoriasis.

  2004cites this paper
• Pimecrolimus – an anti‐inflammatory drug targeting the skin

  2004cites this paper
• RXR- and RAR-selective retinoids in psoriasis and (pre)malignant skin disorders

  2003cites this paper
• [New immunosuppressive agents for treating psoriasis].

  2003cites this paper
• Cyclosporine in the Treatment of Severe Psoriasis

  2003cites this paper
• Otras aplicaciones de tacrolimus tópico

  2003cites this paper
• Makrolide und Ascomycine: Neue antientzündliche Therapieoptionen

  2003cites this paper
• Current systemic therapies for psoriasis: where are we now?

  2003cites this paper
• Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.

  2003cites this paper
• Neue Immunsuppressiva in der Therapie der Psoriasis

  2003cites this paper
• Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.

  2002cites this paper
• Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated.

  2002cites this paper
• Calcineurin‐Hemmer und Sirolimus: Wirkmechanismen und Anwendung in der Dermatologie

  2002cites this paper
• Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology

  2002cites this paper
• Topical Tacrolimus for the Treatment of Oral Lichen Planus

  2002cites this paper
• Tacrolimus: a review of its use for the management of dermatoses

  2002cites this paper
• Novel Therapies for Psoriasis

  2002cites this paper
• What criteria do patients use when judging the effectiveness of psoriasis management?

  2002cites this paper
• Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A.

  2002cites this paper
• New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications.

  2002cites this paper
• Medical backgrounder: psoriasis.

  2002cites this paper
• Cyclosporine and tacrolimus in dermatology.

  2001cites this paper
• Tacrolimus clinical studies for atopic dermatitis and other conditions.

  2001cites this paper
• Anti-CD11a Ameliorates Disease in the Human Psoriatic Skin–SCID Mouse Transplant Model: Comparison of Antibody to CD11a with Cyclosporin A and Clobetasol Propionate

  2001cites this paper
• Interferon-gamma-induced RANTES production by human keratinocytes is enhanced by IL-1beta, TNF-alpha, IL-4 and IL-13 and is inhibited by dexamethasone and tacrolimus.

  2001cites this paper
• Tacrolimus in Dermatology

  2001cites this paper
• Macrolactam immunomodulators for topical treatment of inflammatory skin diseases.

  2001cites this paper
• Topical tacrolimus for the treatment of inflammatory skin diseases

  2001cites this paper
• Successful treatment of erosive lichen planus with topical tacrolimus.

  2001cites this paper
• Topical tacrolimus and pimecrolimus: future directions.

  2001cites this paper
• Tacrolimus in Dermatologic Disorders

  2001cites this paper
• CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement.

  2001cites this paper
• Topical immunomodulatory agents and their targets in inflammatory skin diseases.

  2001cites this paper
• New dermatological agents for the treatment of psoriasis.

  2001cites this paper
• Etiopatogenia de la psoriasis (II). Patogenia

  2001cites this paper
• Modulation of pro-inflammatory cytokines in normal and inflamed skin

  2001cites this paper